Amlodipine-Candesartan Combination: A Cost-Effective Strategy for Successful Therapy of Hypertension
Main Article Content
Abstract
Introduction: The combination of amlodipine and candesartan can have a better effect, although the cost-effectiveness analysis was not yet determined. This research aimed to establish the Incremental Cost-Effectiveness Ratio (ICER) value among outpatients with hypertension who used amlodipine-candesartan. Method: This research is a descriptive study that retrospectively gathered data from medical records. It focused on information for hypertensive patients at Universitas Andalas Hospital in 2021. This study compared the standard treatment involving amlodipine-candesartan and sole amlodipine, next to calculate the ICER using cost-effectiveness analysis. Results: Out of the total population of 284, as many as 73 patients were involved in this study. Among these, 21 patients (28.77%) were treated with amlodipine alone, while 52 (71.23%) received an amlodipine-candesartan combination. The Incremental Cost-Effectiveness Ratio (ICER) for reducing systolic blood pressure was IDR 74,738.10 per one mmHg decrease in the northeast quadrant of the cost-effectiveness chart. The ICER for lowering diastolic blood pressure was IDR 205,918.24 per one mmHg decrease in the northeast quadrant on the cost-effectiveness chart. Conclusion: The cost of the amlodipine-candesartan combination yields superior effects; however, warranting a probabilistic sensitivity analysis to determine its ICER robustness is essential for its effective implementation
Article Details
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The authors retain the copyright and grant the journal the right of first publication simultaneously under the Creative Commons Attribution License. This license allows others to share the work with proper acknowledgment of authorship and initial publication in this journal. Authors are permitted and encouraged to deposit their articles in institutional repositories, on their personal websites, or in other online repositories after the article has been published in JSFK.
References
. Kato H, Shiraishi T, Ueda S, Kubo E, Shima T, Nagura M, et al. Blood pressure control and satisfaction of hypertensive patients following a switch to combined drugs of an angiotensin receptor blocker and a calcium channel blocker in clinical practice of nephrology. Clin Exp Nephrol. 2015;19(3):465–73. https://doi.org/10.1007/s10157-014-1017-7
. Nuraini B. Risk Factors of Hypertension. J Major. 2015;4(5):10–9.
. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223–37. https://doi.org/10.1038/s41581-019-0244-2
. Park C, Wang G, Durthaler JM, Fang J. Cost-effectiveness Analyses of Antihypertensive Medicines: A Systematic Review. Am J Prev Med. 2017;53(6S2):S131–42. https://doi.org/10.1016/j.amepre.2017.06.020
. National Institute of Health Research and Development. Laporan Provinsi Sumatera Barat Riskesdas 2018. Jakarta: Kemenkes RI; 2019.
. Sohn IS, Kim C-J, Ahn T, Youn H-J, Jeon H-K, Ihm SH, et al. Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial. Clin Ther. 2017;39(8):1628–38. https://doi.org/10.1016/j.clinthera.2017.06.014
. Koyanagi R, Hagiwara N, Yamaguchi J, Kawada-Watanabe E, Haruta S, Takagi A, et al. Efficacy of the combination of amlodipine and candesartan in hypertensive patients with coronary artery disease: a subanalysis of the HIJ-CREATE study. J Cardiol. 2013;62(4):217–23. https://doi.org/10.1016/j.jjcc.2013.04.004
. Baroroh F, Sari A, Masruroh N. Cost Effectiveness Analysis of Candesartan Therapy in Comparison to Candesartan-Amlodipine Therapy on Hypertensive Outpatients. Open access Maced J Med Sci. 2019;7(22):3837–40. https://doi.org/10.3889/oamjms.2019.515
. Schäfer HH, Scheunert U. Costs of current antihypertensive therapy in Switzerland: an economic evaluation of 3,489 patients in primary care. Swiss Med Wkly. 2013;143:w13854. https://doi.org/10.4414/smw.2013.13854
. Shiri T, Birungi J, Garrib A V., Kivuyo SL, Namakoola I, Mghamba J, et al. Patient and health provider costs of integrated HIV, diabetes and hypertension ambulatory health services in low-income settings — an empirical socio-economic cohort study in Tanzania and Uganda. BMC Med. 2021;19(1):1–15. https://doi.org/10.1186/s12916-021-02094-2
. Schultz BG, Tilton J, Jun J, Scott-Horton T, Quach D, Touchette DR. Cost-Effectiveness Analysis of a Pharmacist-Led Medication Therapy Management Program: Hypertension Management. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2021;24(4):522–9. https://doi.org/10.1016/j.jval.2020.10.008
. Gottwald-Hostalek U, Sun N, Barho C, Hildemann S. Management of Hypertension With a Fixed-Dose (Single-Pill) Combination of Bisoprolol and Amlodipine. Vol. 6, Clinical pharmacology in drug development. United States; 2017. p. 9–18. https://doi.org/10.1002/cpdd.309
. Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations. Value Heal. 2022;25(1):3–9. https://doi.org/10.1016/j.jval.2021.11.1351
. Pusat Pembiayaan dan Jaminan Kesehatan, Kementrian Kesehatan RI, Kemenkes RI. Buku Panduan Penilaian Teknologi Kesehatan Efektivitas Klinis dan Evaluasi Ekonomi. 2017;p 1-44.
. Fitria N, Andela M, Syaputri YZ. Analisis Efektivitas Biaya Penggunaan Metformin- Glimepirid Terhadap Penurunan Kadar Gula Darah Puasa Pada Pasien Diabetes Mellitus Tipe 2 di Rumah Sakit Universitas Andalas. 2022;202–7. https://doi.org/10.25077/jsfk.9.sup.202-207.2022
. Fitria N, Fitri Anggraini L, Oktavia Sari Y. Cost-Effectiveness Analysis of the Combination of Metformin-Insulin Glargine and Metformin-Glimepiride in Type 2 Diabetes Mellitus Patients in Rupit Hospital. Vol. 1, Journal of Health Economic and Policy Research JHEPR. Purwokerto; 2023.
. Andy F. Discover statistics using SPSS-third edition. Vol. 82, Revista Mexicana de Biodiversidad. 2011. 179–191 p.
. Fitria N, Andela M, Rerita R, Nasif H. Cost-effectiveness of metformin-glimepiride combination compared to single metformin use in decreasing 2 h post prandial blood glucose. 2024;16(1).
. National Institute of Health Research and Development. Laporan Nasional Riskesdas 2018. Jakarta: Kemenkes RI; 2019.
. Astutik E, Puspikawati SI, Dewi DMSK, Mandagi AM, Sebayang SK. Prevalence and Risk Factors of High Blood Pressure among Adults in Banyuwangi Coastal Communities, Indonesia. Ethiop J Health Sci. 2020;30(6):941–50. https://doi.org/10.4314/ejhs.v30i6.12
. Fitria N, Sari YO, Ananta FT, Husnia K. Adherence Assessment on Hypertension Therapy Using The Pill Count Method in Lubuk Kilangan Health Center , Indonesia | Apr N. 2023;69–75. https://doi.org/10.25077/jsfk.10.1.69-75.2023
. Di Chiara T, Scaglione A, Corrao S, Argano C, Pinto A, Scaglione R. Education and hypertension: impact on global cardiovascular risk. Acta Cardiol. 2017;72(5):507–13. https://doi.org/10.1080/00015385.2017.1297626
. Kulkarni J, Gavrilidis E, Worsley R, Rheenen T Van, Hayes E. The role of estrogen in the treatment of men with schizophrenia. Int J Endocrinol Metab. 2013;11(3):129–36. https://doi.org/10.5812/ijem.6615
. Wenger NK, Arnold A, Bairey Merz CN, Cooper-DeHoff RM, Ferdinand KC, Fleg JL, et al. Hypertension Across a Woman’s Life Cycle. J Am Coll Cardiol. 2018;71(16):1797–813. https://doi.org/10.1016/j.jacc.2018.02.033
. Sheppard JP, Burt J, Lown M, Temple E, Lowe R, Fraser R, et al. Effect of Antihypertensive Medication Reduction vs Usual Care on Short-term Blood Pressure Control in Patients With Hypertension Aged 80 Years and Older: The OPTIMISE Randomized Clinical Trial. JAMA. 2020;323(20):2039–51. https://doi.org/10.1001/jama.2020.4871